Feature | Cardiovascular Business | August 01, 2023 | By Melinda Taschetta-Millane

What Viewers Were Reading in July

Here's a look at what viewers found most interesting during the month of July

Here is a look at what DAIC viewers were reading during the month of July

Here is a look at what DAIC viewers were reading during the month of July:

1. Lessons Learned from World’s First Successful Transplant of Genetically-Modified Pig Heart into Human Patient

2. First U.S. Patients Implanted with Innovative FIRE1 Remote Heart Failure Monitoring System in Early Feasibility Study

3. Medtronic Recalls ICDs and CRT-Ds for Risk of Low or No Energy Output During High Voltage Therapy

4. FDA Approves Expanded Indication for Leqvio

5. Abbott Receives FDA Approval for World's First Dual-Chamber Leadless Pacemaker

6. Onecrea Medical Announces the Successful Completion of the First-in-human Implants of its Crea Aortic Valve

7. U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease

8. Abiomed Recalls All Impella Left Sided Blood Pumps for Risk of Motor Damage After Contact with Transcatheter Aortic Valve Replacement (TAVR) Stent

9. Biosense Webster Completes Enrollment in Pivotal Trial Evaluating PFA and RF Dual Energy Catheter for Patients with Atrial Fibrillation in Europe

10. BIOTRONIK Receives FDA Approval For Next-Generation Family of Pacemakers

Log in or register to post comments

Related Content

CorVascular’s VasoGuard Earns FDA 510(k) Clearance

July 29, 2024 — CorVascular, a leading producer of peripheral arterial disease (PAD) / peripheral vascular disease (PVD) ...

July 29, 2024

Globally approved maximum diameter expansion aims to provide new options in larger diameter and tapered vessels

FDA Issues Left Ventricular Assist System (LVAS) Monitor Correction: Abbott Issues Correction for HeartMate LVAS System Monitor due to Screen Issues that May Cause Unintentional Pump Stop

July 2, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott has issued a correction for its ...

July 02, 2024

Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary Bioadaptor System, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

June 18, 2024 — Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary ...

June 18, 2024

EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market

Elutia Announces FDA Clearance of EluPro: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

June 17, 2024 — Elutia Inc., a pioneer in drug-eluting biomatrix products, today announced that its Antibiotic-Eluting ...

June 17, 2024

Xeltis synthetic restorative pulmonary heart valve evolves into a fully functioning, natural heart valve through colonization by the patient’s own tissue.

Xeltis Receives IDE Approval from FDA for Initiation of US Pivotal Trial for aXess, its Restorative Vascular Access Conduit

June 13, 2024 — Xeltis, a leading developer of transformative implants that enable the natural creation of living and ...

June 13, 2024

Heuron ICH has received FDA 510(k) clearance

Heuron Gets FDA Green Light for Stroke Triage and Notification Solution

June 3, 2024 — Heuron, a specialized medical AI startup focused on brain and neurological disorders based in South Korea ...

June 03, 2024

Cutting-edge tool analyzes data from cardiac remote monitoring devices to assess whether a patient is at high risk of experiencing worsening heart failure, enabling medical teams to intervene and avoid hospitalization.

Implicity Earns FDA Clearance for New Heart Failure Prediction Algorithm

May 17, 2024 — Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has ...

May 17, 2024

Abbott recalls HeartMate 3 left ventricular assist system (LVAS) implant kit for risk of blood leakage or air entering system between inflow cannula and apical cuff

FDA Announces Abbott Recall of HeartMate 3 Left Ventricular Assist System (LVAS) Implant Kit

May 15, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling the HeartMate 3 LVAS by ...

May 15, 2024

The US Food and Drug Administration is alerting health care providers and facilities about our continued safety and quality concerns with the following Getinge/Maquet cardiovascular medical devices

FDA Notes Safety and Quality Concerns with Getinge/Maquet Cardiovascular Devices

May 8, 2024 — The US Food and Drug Administration (FDA) is alerting health care providers and facilities about our ...

May 08, 2024

4C Medical's AltaValve System Secures Dual FDA Breakthrough Device Designations, Expediting Patient Access to Advanced Mitral Valve Therapies

May 8, 2024 — 4C Medical Technologies, Inc. ("4C Medical"), a medical device company dedicated to advancing minimally ...

May 08, 2024

© Copyright Wainscot Media. All Rights Reserved.